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Abstract
Pancreatic carcinoma accounts for the most dismal survival among all malignancies with 5-year survival rates approaching
5%. The reason for this, besides the inherent biologic nature of the disease, is the fact that the patients tend to present late in
the disease. We present a review of the current published data on cystic neoplasms of the pancreas, which though rare,
constitute an important subgroup of pancreatic neoplasms that have a better prognosis and are potentially curable lesions.
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Introduction
Cystic pancreatic neoplasms are tumours that have
frequently been misdiagnosed or under-diagnosed.
A commonly encountered folly has been the misdiag-
nosis of these tumours as pseudocysts and their
consequent mismanagement. This has been due to
the relative lack of awareness and also the lack of
knowledge of the diagnostic and therapeutic modal-
ities available. In the modern era of highly sensitive
radiologic investigations, primary cystic neoplasms
are increasingly being detected incidentally. Endo-
scopic ultrasound (EUS), helical computed tomogra-
phy (CT) scan (Figure 1), magnetic resonance
imaging (MRI), and tumour markers (CEA, CA 19-
9 and CA125), have enabled differentiation not only
between the various types but also the subtypes of
cystic pancreatic tumours. This attains significance
from the perspective of radicality of surgery for
mucinous and serous cystic neoplasms. The prognosis
of primary cystic pancreatic neoplasms depends on
the histologic type, as well as invasiveness of the
tumour. The therapeutic principles are now well
defined in this subset of pancreatic tumours.
This review aims to provide an insight into the
various types of primary pancreatic cystic neoplasms,
their behaviour, treatment and prognosis, taking into
account the fact that while they may be referred to
under one big heading, each entity is actually unique
in its pathology, presentation and management.
Incidence
Cystic tumours constitute 10% of cystic lesions of the
pancreas, showing all stages of cellular differentiation
from benign to highly malignant tumours [1]. Benign
(serous and mucinous) cystadenomas and cystadeno-
carcinomas constitute three-quarters of these cystic
tumours [2]. These cystic neoplasms account for
110% of all pancreatic malignancies [1,3,4]. The
incidence of radiologically detected pancreatic cystic
neoplasms in screening varied from 0.2% [5] when
ultrasonography was used to 0.7% [6] in a study using
CT and MRI scans.
Serous cystic neoplasms predominantly affect wo-
men (65%), with an average age of 62 years (range
3584 years) [7]. They account for 3239% of cystic
tumours of the pancreas [8]. Mucinous cystic neo-
plasms also affect predominantly women (95%),
with an average age of 53 years (range 1982 years)
[9,10]. They constitute 1045% of cystic pancreatic
neoplasms. Together with the above two, intraductal
papillary mucinous neoplasms of the pancreas
(IPMNs) accounting for 2133%, comprise the three
most commonly encountered tumours [8]. IPMNs
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occur a little more commonly in males at an average
age of 65 years. Solid papillary epithelial neoplasias
(SPENs) are tumours that predominantly occur in
females in the third to fourth decade of life [8,11].
Non-functioning islet cell tumours (NFITs) with
cystic degeneration occur at an average age of 53 years
[12]. Acinar cell cystadenocarcinoma most commonly
occurs in males and constitutesB1% of cystic
tumours [8].
Pathological classification
The four main classes of cystic pancreatic tumours
[10] include serous cystic, mucinous cystic, intraduc-
tal papillary mucinous, and the other unusual neo-
plasms, including SPENs. The WHO classification is
listed in Table I [13].
Clinical presentation
Up to 4075% of patients with cystic pancreatic
tumours are asymptomatic [14], with the majority
being detected incidentally on imaging modalities.
Symptoms, when present, are a result of pressure
effects and are more common in mucinous lesions
 the incidence of symptoms correlating with the risk
of malignancy [15]. The most commonly encountered
symptoms are abdominal pain, weight loss and nausea
[16]. The less common symptoms are constipation,
diarrhoea, abdominal distension, fatigue, early satiety
and, in the rare event of functioning tumours, the
patient may show signs of hypoglycaemia [17].
Jaundice, as a symptom, is uncommon in serous
neoplasms even if the lesion is of a large size. In
contrast, it is seen in 2554% patients with mucinous
tumours in the head of the gland [10,18]. As such, a
patient presenting with a large lesion in the head and
neck of the pancreas without jaundice, should arouse
the suspicion of a cystic neoplasm. A prior history of
pancreatitis is largely confirmatory of pseudocysts,
although the occasional cystic neoplasm may give rise
to an attack of pancreatitis following partial duct
obstruction [10]. Bleeding-related complications sec-
ondary to gastric involvement, portal hypertension,
haemobilia or haemosuccus pancreaticus, can be seen
in malignant mucinous neoplasms [19,20]. In rare
cases of SPEN, patients have presented with acute
abdominal pain due to rupture of the tumour [21].
IPMNs, when symptomatic, present with signs of
chronic pancreatitis and pancreatic exocrine insuffi-
ciency, i.e. pain, steatorrhoea, weight loss, diabetes,
etc. They can also present as acute or recurrent
pancreatitis. The main distinguishing feature is the
lack of aetiology for acute pancreatitis on obtaining a
history in such a patient. Diabetes is found to be
associated with mucinous tumours, especially those
that are malignant [22]. Rare associations with Peutz-
Jeghers and Zollinger Ellison syndrome have been
described [23,24]. On examination, a palpable mass
may be detectable in cases of malignant mucinous
cystic lesions [18].
Pathology (Figures 2 and 3)
Serous cystadenomas (SCAs) vary in size from 6 to
10 cm, although cysts of even 25 cm have been
reported. They are well demarcated and are lined
by simple, glycogen-rich cuboidal epithelium and
Figure 1. Coronal reformation of contrast-enhanced abdominal
MDCT showing a large cystic mass with well defined smooth walls.
Also seen is an irregular solid component along the left lateral and
superior walls. The mass is in close contact with the pancreatic head
(white arrow) and the portal vein is seen medial to it (black arrow).
Table I. WHO classification of cystic pancreatic tumours [13].
Serous microcystic adenoma
Serous oligocystic adenoma
Serous cystadenocarcinomas
Mucinous cystadenoma
Mucinous cystic neoplasm  borderline
Mucinous cystadenocarcinomas
 Non-invasive
 Invasive
Intraductal papillary mucinous neoplasm
Intraductal papillary mucinous adenoma
Intraductal papillary mucinous neoplasm  borderline
Intraductal papillary mucinous carcinoma
 Non-invasive
 Invasive
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characterized by a dense, lace-like, honeycombed
matrix of fibrous septae. They have been referred to
as microcystic as they are made up of clusters of cysts
that are filled with clear watery, non-mucinous and
occasionally bloody fluid.
Mucinous neoplasms are made up of cysts that are
larger in size than the serous neoplasias and are
usually up to 25 cm. The cyst contains clear, muci-
nous, viscid fluid. The main features that help in
distinguishing it from other cystic neoplasias are the
presence of a dense mesenchymal ovarian-like stroma
and the lack of communication with the main
pancreatic ductal system [25,26]. Furukawa et al.
[27] had earlier divided mucus-hypersecreting tu-
mours into four types based on their gross features,
i.e. (1) uniformly dilated main duct; (2) focally dila-
ted main duct; (3) cystic sub-branches; and (4)
dilated sub-branches. The Mayo Clinic has recently
divided these tumours, for purposes of treatment, into
three subgroups [28]: (a) mucinous cystadenomas
(MCAs) (65%); (b) non-invasive proliferative MCNs
(30%), with and without dysplasia; and (c) mucinous
cystadenocarcinomas.
IPMNs are characterized by papillae (intestinal,
hepatobiliary, gastric, or rarely, oncocytic) [2932]
arising from the intraductal proliferation of neoplastic
mucinous cells. It is associated with the dilatation of
the pancreatic duct and/or the ductal side branches
that contain mucin. They have been seen to possess
four predominant patterns [14]: (1) diffuse main
pancreatic duct ectasia; (2) segmental main pancrea-
tic duct ectasia; (3) side-branch duct ectasia (‘branch-
duct’ type); (4) unifocal and multifocal cysts with
pancreatic duct communication.
Solid and cystic papillary and epithelial neoplasias
(SPENs) have a variegated appearance with solid,
cystic and papillary areas with foci of necrosis and
haemorrhages. The degenerative areas have been
attributed to vascular ischaemia [33]. The most useful
markers are alpha-1-antitrypsin, alpha-1-antichymo-
trypsin, neuron specific enolase (NSE) and vimentin
[34].
Lew et al. [35] in their recent publication have
raised the issue of mucinous ductal ectasia (MDE) as
a less known entity often confused with mucinous
cystic neoplasms. According to them, MDEs are
characterized by dilated primary and secondary ducts
filled with thick mucus that appear as a mass or cyst
on imaging [35]. The existence of MDE as an entirely
separate entity has been strongly contested by Rivera
et al. [36], who had suggested that this may actually
be a subgroup of intraductal papillary neoplasms
(IPNs). They felt that the introduction of the term
IPMN should broadly encompass the entire spectrum
of these neoplasms.
Diagnosis (Algorithm 1)
Ultrasonography is a useful basic investigation as it
can help differentiate a solid from a cystic lesion but it
does not permit a complete characterization due to
the presence of bowel gas that often obscures vision.
CT scan is the most favoured initial diagnostic test
for cystic tumours of the pancreas. It is not only useful
in the diagnosis but also helps in characterization of
the lesion based on calcification of the cyst wall, septa,
mural nodules and the findings suggestive of pancrea-
titis [3739]. Enhanced CT with bolus injection of
contrast medium and thin collimation is useful in
differentiating SCA from mucinous cystic neoplasms
(MCNs).
Appearances
SCA  water, soft tissue or mixed density; poorly
defined to thin, well defined capsule; multiple, small
(B2 cm) well-defined cysts, central calcifications, and
enhancement around microcysts after contrast admin-
istration.
MCA  near water density unilocular or multi-
locular large cysts with enhancing walls and septa, and
peripheral calcifications.
Mucinous cystadenocarcinomas (MCACs)  thick-
walled (2 mm) macrocysts, with septations, a solid
component and a peripheral rim of calcifications.
Figure 2. Photomicrograph showing cystic mucinous neoplasm of
pancreas with mild dysplasia (H&E stain,20).
Figure 3. Photomicrograph showing serous microcystic adenoma of
pancreas (H&E stain,20).
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IPMN  segmental or diffuse dilatation of the
pancreatic ductal system. In side-branch IPMT,
involvement is limited to segmental ducts, resulting
in a solitary cystic mass with an otherwise normal
ductal system [40].
NFIT and SPEN  hypervascular peripheral solid
components and central cystic.
Atypical SCAs may appear as solid masses due to
innumerable tiny cysts below the resolution of ima-
ging equipment, or they may contain larger cysts
similar to those of MCN. In this respect, some
malignant cystic lesions mimic the appearance of a
pseudocyst or other benign lesions.
MRCP
MRI provides a better characterization of the mor-
phology of the cyst. In the case of IPMN it is being
strongly advocated as the diagnostic modality of
choice. Its advantage over ERCP stems from its ability
to image the pancreatic duct anatomy/configuration
and size [41], as filling of the side branch ducts may
be obscured by intraductal mucin plugs in ERCP
[42].
Taouli et al. [43] have shown that certain features
of IPMN detected on MRI may actually indicate
a higher probability of a malignancy, i.e. presence
of a solid mass, main pancreatic duct dilatation
(10 mm), diffuse or multifocal involvement, and
attenuating or calcified intraluminal content.
ERCP
ERCP plays a role in identifying the ductal anatomy
and delineating the presence of any communication
between the cyst and the duct that may be present in
up to 65% cases [33]. It is useful in differentiating
an MCN for chronic pancreatitis from IPMN. The
main indication was the diagnosis of IPMN based on
the demonstration of the communication of the
tumour with the main duct and the side branches,
as well as discharge of mucin from the ampulla  an
indication that is being strongly challenged by advo-
cates of MRCP. It is still an important investigation in
the exceptional case of a patient with a cystic mass in
the head of the pancreas very close to the main duct of
Wirsung and where a differentiation between IPMN
and even a serous cyst adenocarcinoma appears
difficult and necessitates the demonstration of the
relationship between the mass and the duct [44].
Angiography
The vascularity of the tumour and the peripancreatic
region can be studied with the help of angiography
that can help to differentiate a hypervascular tumour
from hypovascular pseudocysts [45]. It has been seen
though that cystic tumours may also be hypovascular
simulating pseudocysts. With the availability of better
non-invasive diagnostic tests, the need for angiogra-
phy has reduced. Its influence on guiding treatment
has been down-played by the fact that surgeons today
have a better understanding of the anatomy and as
such do not need an additional test to define the
vascular status preoperatively.
EUS
The main role for EUS in cystic pancreatic neoplasias
is to provide a detailed morphology of the cystic lesion
(including the presence of intramural nodules in
IPMN) and to guide fine-needle aspiration cytology
(FNAC) of the lesion [46,47]. It has its limitations in
differentiating mucinous from non-mucinous cystic
lesions [48] due to its low sensitivity and specificity,
i.e. 38.9% and 75.0%, respectively [16]. This also
causes difficulty in differentiating benign from malig-
nant lesions [49].
Cyst fluid analysis
Today, the analysis of the cyst fluid obtained from an
EUS-guided aspiration provides valuable information
if analysed for biochemistry, tumour markers and not
only cells as these aspirates tend to be paucicellular. In
general, glycogen-rich cells are specific for serous
cystadenoma, mucin-containing cells are seen in
mucinous cystadenomas, and malignant cells are seen
in mucinous cystadenocarcinomas [12]. Potential
complications of FNA include spillage of malignant
cells into the peritoneum, haemorrhage and injury
to adjacent organs.Table II shows the various com-
ponents that are analysed and the quantities in which
Symptoms of vague
pain in abdomen +/–
lump in abdomen
Abdominal
ultrasonography
CT scan
EUS with FNA and
fluid analysis
E/o chronic pancreatitis
? IPMN ? Pseudocysts
ERCP/MRCP
Diagnosis confirmed
Algorithm 1. Diagnostic algorithm for cystic pancreatic tumours.
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they are found in the various common neoplasias
[8,10,5052].
PET scan
Sperti et al. [53] have suggested that 18-FDG PET
may be better than CT and tumour marker assays in
the preoperative evaluation of patients with cystic
pancreatic lesions, as a positive result strongly sug-
gests malignancy, and hence surgery, while a negative
result implies a benign lesion that may be treated by
limited resection or, in selected high- risk patients,
with biopsy, follow-up, or both.
Management
The treatment of cystic pancreatic tumours depends
on the probable diagnosis, as the likelihood of
malignancy is closely related to the type of histology.
The possibility of malignancy in a serous cystic
tumour is as low as 3% [54], while main duct IPMNs
have a 70% chance of being malignant [55]. Muci-
nous cystic tumours can be best considered as
premalignant.
With the increased diagnosis of incidental tumours
because of high quality imaging, we are now also
faced with the decision of whether to operate these
patients with lesionsB3 cm. While Sahani et al. [56]
have found that lesionsB3 cm are usually benign,
Kiely et al. [57] have stressed the need for enucleation
even in patients with lesionsB2 cm, as long as the
patient can withstand the surgery. This recommenda-
tion is based on a high incidence of false negatives
seen in investigations. Allen et al. [58] in a recent large
series of 539 cases spanning 10 years have concluded
that selected patients with cystic lesions B3 cm in
diameter and without a solid component may be
followed radiographically with a malignancy risk that
approximates the risk of mortality from resection.
This is based on the premise that small mucinous
lesions are unlikely to be malignant.
The currently accepted guidelines are that for SCAs,
an organ-preserving resection should be carried out,
although there are proponents of a conservative line of
management [59,60]. A fair consensus is that lesions
that are asymptomatic and/or B4 cm in size can be
followed up at yearly intervals, while surgery should be
offered to patients with symptomatic lesions and
tumours 4 cm, because they have been seen to
grow at a rate of almost 1.98 cm/year [61].
In the case of mucinous tumours, a more radical
resection is advised [59]. This is based on the under-
standing of its malignant potential. As these tumours
usually occur in the fifth decade, the likelihood of a
malignant transformation is also high. In the presence
of predictors of malignancy, such as large tumour size,
mural nodules and egg-shell calcification, spleen-
preserving techniques should be avoided to obtain a
correct oncological lymph node dissection [55,62].
In the case of IPMN, where the tendency is for the
tumour to grow along the ducts rather than radially
into the parenchyma, the resection margins must be
examined by frozen section intraoperatively to con-
firm the clearance of the margins. The current
recommendation is to resect all main duct and mixed
variant IPMNs as long as the patient is a good surgical
candidate with a reasonable life expectancy [55].
Routine total pancreatectomy is not indicated and
should be performed only for obvious extensive, but
resectable, histologically confirmed disease involving
the entire gland [63].
The issue of management of pure branch-type
IPMNs remains to be resolved, with conflicting data
on whether a conservative approach [64] or an
anatomic resection should be performed [63]. The
IAP consensus for management of IPMNs [55] has
attempted to put some of these doubts to rest by
recommending surgery for symptomatic lesions.
However, they have added that other indications
could include patients willing for surgery and un-
likelihood of follow-up. This remains an option only if
a safe pancreatic resection is available. The ideal
management of branch-duct IPMNs30 mm and
without main duct dilation or mural bodies awaits
further evidence.
Intraoperative ultrasonography can assist in differ-
entiating a pseudocyst from a cystic neoplasm [12],
although a preoperative history of severe acute pan-
creatitis coupled with the imaging showing intracystic
septae and nodules should make the differentiation
easier. Caution is required because inflammatory
precipitations may mimic the neoplastic features. In
Table II. Cyst fluid analysis [8,10,4244].
Component
Serous
cystadenoma
Mucinous
cystadenoma
Mucinous
cystadenocarcinoma
Intraductal papillary
mucinous neoplasia Pseudocyst
Amylase (B250 U/l) Low Low Low High High
CEA (ng/ml) B5 800 800 5800 B5
CA 19-9 (U/ml) B37 Variable Variable Variable B37
CA 15-3 Low High High Low Low
TAG 72 (U/ml) B3 3137 780 High B5.7
Malignant cells Absent Absent Present Absent Absent
CA 125 Low Variable Variable Low Low
Viscosity Low High High High low
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contrast, some cystadenocarcinomas lack the charac-
teristics of malignancy and even gross inspection may
lead to a misdiagnosis [65,66].
For lesions located at the pancreatic body and tail
(Figure 4), a segmental or distal pancreatectomy, with
preservation of the spleen where possible, is recom-
mended [6771]. In case of cystic masses that are
malignant or potentially malignant in the head of the
pancreas, a pancreaticoduodenectomy is the preferred
option, but an enucleation can be performed if there is
an accurate diagnosis of a benign lesion.
Indications for a ‘wait and see’ policy in MCNs and
IPMNs include [55]: (1) symptomatic cysts without
main duct dilatation (6 mm), (2) those without
mural bodies, and (3) thoseB30 mm in size. The
ideal investigations for monitoring such patients
would be CT or MRCP and EUS.
The suggested interval between follow-up examina-
tions would appear to be yearly for lesionsB10 mm in
size, 612 monthly follow-up for lesions between
10 and 20 mm, and 36 monthly follow-up for
lesions20 mm. The interval can be lengthened after
2 years of stationary findings. Indications for giving up
the conservative management would include the
appearance of symptoms, and findings contrary to
those listed above.
The overall 5-year survival nears 100% for SCA
and even MCA where the resection margins are clear
and there is no evidence of transmural invasion
[8,14]. Even in IPMNs containing carcinoma,
5-year survival is over 50% [72].
Walsh et al. [73] have even suggested that with the
increasing incidence of ‘incidentally’ detected asymp-
tomatic pancreatic cysts, if a mucinous neoplasm can
be excluded with confidence, an EUS-guided aspira-
tion can be done and the patient can be followed up
clinically and with interval imaging. One of the
reasons for EUS aspiration is that it permits the
detection of mucin extrusion seen in a case of a
mucinous neoplasm.
A few reports exist on the use of chemotherapy, and
occasionally, radiotherapy in the adjuvant setting. The
indications enlisted have been evidence of tissue
invasiveness [74,75] in the pathological specimen,
liver metastasis (chemoembolization) [76], unresect-
able tumour (radiotherapy) [77], large tumours
(neoadjuvant chemotherapy to downsize the tumour
for surgery) [78], and with aneuploid neoplasms [79].
Sarr et al. have suggested a role for adjuvant treatment
even in the absence of lymph node metastasis [28].
The role of chemoradiation, whether in the adjuvant
or neoadjuvant setting, requires more studies to prove
the efficacy. Maire et al. [80] have suggested that in
the absence of current evidence for adjuvant therapy
in pancreatic cancer, patients with locally advanced
malignant cystic neoplasms, especially IPMNs,
should be included in the same protocols assessing
adjuvant chemotherapy and radiotherapy regimens as
patients with ductal adenocarcinoma.
The authors have published their own institutional
review of SPENP [81]. They reported good outcomes
with a median survival of 36 months following resec-
tional surgery of this tumour. They concluded that an
increased awareness of this subgroup of pancreatic
tumours is important.
Summary
Cystic neoplasms constitute an important group of
pancreatic neoplasias with a good prognosis if diag-
nosed early and managed appropriately. MRCP is
now emerging as the diagnostic modality of choice for
IPMN, in addition to being able to differentiate
IPMN from MCN and chronic pancreatitis. CT
scan is an important modality in the diagnostic
armamentarium. Cyst fluid analysis obtained using
EUS following aspiration is another diagnostic mod-
ality that may help to differentiate the various cystic
neoplasms. Mucinous tumours should be resected
radically due to the risk of malignant potential. IPMN
should be subjected to frozen section to confirm
clearance of tumour intraoperatively so as to decide
on the pancreatic remnant.
In case of doubt, it is best that cystic tumours are
resected in centres of pancreatic surgery, as they carry
a better prognosis compared with other pancreatic
tumours.
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